Glen Eagle Advisors’s Medifast MED Stock Holding History

Glen Eagle Advisors’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Hold	0	–	–	–	1158
2024 Q2	–	Hold	0	–	–	–	1142
2024 Q1	–	Sell	-10	Closed	-$484	–	1110
2023 Q4	$674	Hold	10	–	–	﹤0.01%	955
2023 Q3	$733	Hold	10	–	–	﹤0.01%	951
2023 Q2	$889	Buy	10 +1	+11%	+$89	﹤0.01%	967
2023 Q1	$981	Hold	9	–	–	﹤0.01%	958
2022 Q4	$1.08K	Hold	9	–	–	﹤0.01%	1009
2022 Q3	$994	Hold	9	–	–	﹤0.01%	975
2022 Q2	$1.64K	Hold	9	–	–	﹤0.01%	854
2022 Q1	$1.54K	Hold	9	–	–	﹤0.01%	842
2021 Q4	$1.89K	Hold	9	–	–	﹤0.01%	812
2021 Q3	$1.73K	Hold	9	–	–	﹤0.01%	935
2021 Q2	$2.55K	Hold	9	–	–	﹤0.01%	896
2021 Q1	$1.91K	Hold	9	–	–	﹤0.01%	884
2020 Q4	$1.77K	Hold	9	–	–	﹤0.01%	861
2020 Q3	$1.48K	Hold	9	–	–	﹤0.01%	818
2020 Q2	$1.25K	Hold	9	–	–	﹤0.01%	798
2020 Q1	$563	Buy	+9	New	+$819	﹤0.01%	781

Other funds holding MED

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glen Eagle Advisors's MED Position: Q3 2024 in Review

Glen Eagle Advisors held its Medifast (MED) position steady in Q3 2024 at 0 shares worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1158.

Glen Eagle Advisors first reported a position in MED in Q1 2020 and has held it in 16 quarters since. The position peaked at $2.55K in Q2 2021. 140 funds tracked by Wall St. Rank hold MED as of Q3 2024.

Glen Eagle Advisors held 0 shares of Medifast worth $1 as of Q3 2024.
Glen Eagle Advisors left its Medifast share count unchanged in Q3 2024.
Medifast made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q3 2024, its #1158 holding.
Glen Eagle Advisors first reported a position in Medifast in Q1 2020 and has held it in 16 quarters since.
Glen Eagle Advisors's Medifast position peaked at $2.55K in Q2 2021.
140 funds tracked by Wall St. Rank held Medifast as of Q3 2024.

Based on Glen Eagle Advisors's 13F filing for Q3 2024, filed 15 Nov 2024.